AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06326723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: 25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.).
Study NCT05225961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
Study NCT05225961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
Study NCT04688164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet
Study NCT04688164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT05621564 — intervention group
Intervention type: DRUG
Intervention: pre-operative therapy
Description: pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
Study NCT05594342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 7.5Mg Tab
Description: Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
Study NCT05594342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOBUTamine Injectable Solution
Description: Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
Study NCT05594342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOBUTamine Injectable Solution
Description: Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
Study NCT06232382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis audio
Description: * After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Hypnosis audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session (5 minutes).~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires (5 minutes).~* Post-session quality of sleep will be assessed by telephone interview 1 day after session.
Study NCT06232382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation audio
Description: * After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Mindfulness Meditation audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session.
Study NCT06232382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Natural text audio (control audio)
Description: * After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Control audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session.
Study NCT05092659 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient interview
Description: Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
Study NCT06282250 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy
Description: Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions.
Study NCT06282250 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy
Description: Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions.
Study NCT06282250 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psycho-education + Imagery focused Cognitive Therapy
Description: Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions.
Study NCT05585216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma
Description: intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
Study NCT05585216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
Study NCT05066620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal medicine FYTF-919
Description: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
Study NCT05066620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine FYTF-919
Description: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
Study NCT05117944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drama-supported patient role experience
Description: The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
Study NCT06224504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine health education
Description: guided the diet of patients, and introduced the knowledge of the disease in detail
Study NCT06224504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine health education
Description: guided the diet of patients, and introduced the knowledge of the disease in detail
Study NCT04540432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool collection at the patient's home.
Description: Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
Study NCT04540432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: 7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
Study NCT05478200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
Study NCT05478200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
Study NCT04890392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
Description: S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
Study NCT06224504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychological nursing
Description: hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
Study NCT06224504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological nursing
Description: hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
Study NCT05974904 — intervention group
Intervention type: OTHER
Intervention: high-sensitivity C-reactive protein to albumin ratio
Description: High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
Study NCT06224504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR therapy
Description: Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
Study NCT06224504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
Study NCT05874518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm needling combined with electroacupuncture
Description: Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
Study NCT05874518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The treatment with letrozole tablets was started on the fifth day of the menstrual cycle
Description: Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
Study NCT05233410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT05233410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study NCT04325529 — intervention group
Intervention type: DEVICE
Intervention: Aversive stimuli
Description: Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
Study NCT06566352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine
Description: intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution
Study NCT06566352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional laparoscopic myomectomy
Description: traditional laparoscopic myomectomy
Study NCT06566352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
Description: Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
Study NCT06566352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of epinephrine 1mg diluted in 200mg of NaCl
Description: injection of epinephrine 1mg diluted in 200mg of NaCl
Study NCT06346080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Discrete choice survey
Study NCT06409325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MST
Description: MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
Study NCT06409325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
Study NCT05046145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy for chewing + real tDCS
Description: participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
Study NCT05260528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine and Idarubicin
Description: Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3
Study NCT05260528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-315
Description: Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3
Study NCT06008470 — intervention group
Intervention type: OTHER
Intervention: observational tests
Description: Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity
Study NCT05340153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine Drug Combination
Description: Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
Study NCT05340153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine drug combination
Description: Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
Study NCT06109428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg
Study NCT06109428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 125 mg
Study NCT06109428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg
Study NCT06109428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg
Study NCT06109428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g
Study NCT06109428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g
Study NCT05341427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electromagnetic device
Description: electromagnetic waves for burn wound
Study NCT04827576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT06109428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation
Study NCT04827576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle
Study NCT06343077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly-ICLC intramuscular (IM) injection
Description: 1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
Study NCT06343077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly-ICLC, Intertumoral (IT) injection
Description: 1 mg IT once (week 2)
Study NCT05883605 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Measuring blood pressure
Description: Measuring blood pressure using electronic device and using a mercury sphygmomanometer